Drug Profile


Alternative Names: MaxiVax vaccine; MVX-1 loaded autologous tumour vaccine; MVX-1-loaded macrocapsule/autologous tumour cell vaccine - MaxiVax; MVX-ONCO1

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MaxiVax
  • Class Cancer vaccines; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 27 Jun 2017 Phase-II clinical trials in Head and neck cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Switzerland (SC) (NCT02999646) (MaxiVax website, August 2017)
  • 07 Oct 2016 Final adverse events data from a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therpy) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 09 Feb 2016 MaxiVax completes a phase I trial in Solid tumours in Switzerland (MaxiVax website; February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top